The chemical reactions that produce energy.
of
last 6 months
The chemical reactions that produce energy. |
Super Biotechs of last 6 months |
|
New Drug Applications
FDA Press
Announcements
TigerSoft
Blog - AMGEN's 1990-1991 Take Off Remembered 9/6/2007
TigerSoft
Blog - Biotech's Game of Roulette: Bullish Signs 9-21-2007/
January 17, 2014 - FDA allows
marketing for first of-its-kind post-natal test to help diagnose
developmental
delays and intellectual disabilities in children
http://www.affymetrix.com/
January 08, 2014 - FDA
approves Farxiga to treat type 2 diabetes AstraZeneca
--------------------------------------------------------------------------------------------------------------------------
The research I've done on the way the strongest stocks topped
out in 1999-2000 shows several things:
1) Weekly OBV non-confirmations
of new highs gave the
most timely Sells on these stocks. I will be posting weekly
data on all the strongest biotechs on our data page. It
will be included in the regularly weekly data.
2) Many of the 1999-2000 stocks were up 8x-10x their 12-month
lows.
3) 25% were more than 48% above their 21-day ma.
4) Closing Power trend-breaks in the very strongest stocks
was the most common way one could have know that a
top had been made.
5) In the daily charts, Closing Power
NCs and OBV NCs occurred
at 1/2 the tops.
6) Head and shoulders in the daily charts appreared In 1/4 of
the 1999-2000 super stocks as they were topping out.
7) False breakouts occurred in 1/4 of the these stocks.
8) The declines that resulted were swift and punishing to the
longs who ignored them. 30%-50% declines within three months
were the norm. Some were even more severe.
Biotechs over $5
that are up 220% or more
1/23/2014 130-day pct change
This allows better comparisons with 1999-2000 study.
------------------------------------------------------------------------------------
ICPT 326.02
+544%
----->BCRX 12.17
+.03 +496% channel breakout
13.53 is 5-year high - OBV confirming.
BioCryst Pharmaceuticals 40
employees Durham, NC http://www.biocryst.com
- develops novel drugs that block key enzymes involved in the pathogenesis of
diseases.
- in Phase III clinical trials for acute influenza;
IDRA 4.14 -.26
+417% low IP21/ Falling
CP
------>ARWR 11.70 -.29
+331% on channel breakout run
All-time high. OBV is confirming.
Arrowhead Research Corp. 54 employees http://www.arrowheadresearch.com
ARC-520, an RNAi-based therapeutic that has completed a Phase 1 clinical trial for the
treatment of chronic hepatitis B virus (HBV) infection; and
Adipotide, which is in Phase I clinical trial for the treatment for obesity.
CTIC 4.13 +
.12 +289%
up
from 1.75 in a month.
GERN
5.71 +.23
+285%
GALE 6.11 -.27 +243%
Red distribution. CP weak.
OBV H/S pattern.
PRAN
8.85 +.19
+241%
SNMX
7.4 +.33
+236% channel breakout run
8 is 5-year high
ANAC 20.76
+224%
Channel Breakout. Above 20 legitimizes it
for some institutions.
Wkly OBV confirming. Both UP condition.
Focuses on discovering, developing, and
commercializing novel small-molecule
therapeutics derived from its boron chemistry platform. The company's lead product
candidates include tavaborole, an antifungal product candidate that is in Phase III
clinical development for the treatment of onychomycosis; and AN2728, an
anti-inflammatory product candidate, which completed Phase II clinical trials
for the treatment of atopic dermatitis and psoriasis
Anacor
Pharmaceuticals Inc: The Best Performing Biotechs of 2013
An
Eczema Stock That Keeps Breaking Ou
Anacor
Pharmaceuticals Is Not for Everyon
INCY
65.6
+188%
SNMX 7.03
+221%
channel
breakout run
8 is 5-year high
------------------------------------------------------------------------------------------------------------------------------------------------------
------>PBYI
126.52 -3.42 +136%
B10/B12/B20/B24 run
All-time high. OBV is confirming.
http://www.pumabiotechnology.com
49 employees LA,CA
Engages in the acquisition, development, and licensing of products for the treatment of
various
forms of cancer. Its drug candidates include PB272 (neratinib (oral)) for the treatment of
advanced breast cancer patients and non-small cell lung cancer patients; and PB272
(neratinib (intravenous)) for the treatment of advanced cancer patients
JAZZ 159.07 +2.35
+124% Dublin, Ireland
700 employees
products
include:
Xyrem
for the treatment of cataplexy and narcolepsy
Erwinaze
to treat acute lymphoblastic leukemia;
Prialt
for the management of severe chronic pain;
FazaClo
LD and FazaClo HD, tablets for the resistant schizophrenia treatment.
Luvox
CR to treat obsessive compulsive disorder;
Caphosol
to treat oral mucositis;
Quadramet
for the treatment of pain in patients whose cancer has spread to the bones;
ProstaScint
for imaging the extent and spread of prostate cancer;
Niravam
for the treatment of generalized anxiety and panic disorders; and
Parcopa
for the symptoms associated with idiopathic Parkinson?s disease treatment
IDIX
7.84 -.15
+123%
Develops drugs for the treatment of human viral diseases. Its primary research and
development
focus is on the treatment of patients with hepatitis C virus (HCV).
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |